HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Apr.21) - A Brutal Reality, Benign Returns from China Biotech, Pharmaron

China Healthcare Weekly (May.5)- 2nd Wave of COVID, Valuation Logic of China's Core Assets, Lifetech

Acotec Scientific (6669.HK) - What Value Boston Scientific Will Bring Is Crucial to Future Valuation

Pre-IPO MedSci Healthcare Holdings - The Investment Logic, the Business Analysis and the Risks

China Biotech – The Commercialization Performance and The Outlook

ClouDr Group (9955.HK) -  “A Dark Horse” to Beat JD Health

China Traditional Chinese Medicine (570.HK) - The Privatization Rumor and the Outlook

Equity Capital Markets

MedSci Healthcare Holdings / Equity Capital Markets

<ul>
<li>MedSci's profit quality/business structure is “healthier” than Medlive. MedSci is better able to cope with the negative impact of external changes, and its performance growth is more resilient than Medlive.</li>
<li>MedSci’s physician platform solutions business is stronger than Medlive’s medical knowledge solutions business. Considering the logic and significance of this business, MedSci is expected to have bigger growth potential.</li>
<li>If considering the cash balance, MedSci’s IPO valuation seems not that cheap. However, we think MedSci's valuation would narrow the gap with Medlive or even surpass it in the future.</li>
</ul>


MedSci's profit quality/business structure is “healthier” than Medlive. MedSci is better able to cope with the negative impact of external changes, and its performance growth is more resilient than Medlive.
MedSci’s physician platform solutions business is stronger than Medlive’s medical knowledge solutions business. Considering the logic and significance of this business, MedSci is expected to have bigger growth potential.
If considering the cash balance, MedSci’s IPO valuation seems not that cheap. However, we think MedSci's valuation would narrow the gap with Medlive or even surpass it in the future.


Pre IPO MedSci Healthcare Holdings - Some Points Worth the Attention